CD8A and neoplasm: In tumors harvested on day 18 after tumor inoculation, the absolute number of CD8 T cells (Fig. 4b) and Ki67-positive CD8 T cells (Supplementary Fig. 6A) were highest in the combination treatment, but the differences between the anti-CTLA4 only and combination groups were not statistically significant, suggesting that ganetespib treatment does not further increase number or proliferation of CD8 T cells in the tumor.